期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 40, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.nano.2021.102498
关键词
Acute respiratory distress syndrome; Cerium oxide nanoparticles (CNP); microRNA-146a (miR146a); Acute lung injury; Pulmonary fibrosis
资金
- Gates Center Grubstake Award
Acute respiratory distress syndrome (ARDS) is a severe lung disease characterized by oxidative stress and inflammation. Current treatment options for ARDS are limited, and there is a need for new therapeutic approaches. A study found that cerium oxide nanoparticles (CNP) conjugated with anti-inflammatory microRNA-146a (miR146a), known as CNP-miR146a, can prevent acute lung injury in a pre-clinical model. Furthermore, delayed treatment with CNP-miR146a showed potential in rescuing the lung from acute injury.
Acute respiratory distress syndrome (ARDS) is a highly morbid pulmonary disease characterized by hypoxic respiratory failure. Its pathogenesis is characterized by unrestrained oxidative stress and inflammation, with long-term sequelae of pulmonary fibrosis and diminished lung function. Unfortunately, prior therapeutic ARDS trials have failed and therapy is limited to supportive measures. Free radical scavenging cerium oxide nanoparticles (CNP) conjugated to the anti-inflammatory microRNA-146a (miR146a), termed CNPmiR146a, have been shown to prevent acute lung injury in a pre-clinical model. In this study, we evaluated the potential of delayed treatment with CNP-miR146a at three or seven days after injury to rescue the lung from acute injury. We found that intratracheal CNP-miR146a administered three days after injury lowers pulmonary leukocyte infiltration, reduce inflammation and oxidative stress, lower pro-fibrotic gene expression and collagen deposition in the lung, and ultimately improve pulmonary function. (c) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据